Tivic Health FY2024 net loss narrows to $5.7M; secures $25M equity line, in-licenses Entolimod

Valion Bio, Inc.

FY2024 revenue $0.8M (down from $1.2M); net loss -$5.7M vs -$8.2M in 2023 (30% decrease).
Entered $25M equity purchase agreement with Mast Hill Fund; issued 29,800 commitment shares.
In-licensed late-stage TLR5 agonist Entolimod from Statera Biopharma for acute radiation syndrome (Phase III).
Appointed Michael Handley as COO and President of Tivic Biopharma; Lisa Wolf as interim CFO.
ncVNS optimization study completed enrollment; disease-specific trials planned in 2025.

item 1.01 item 2.02 item 7.01 item 3.02 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.